Compare Sanofi SA (SNY) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Twist Bioscience Corp — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Sanofi SA is far larger — about 19.2× Twist Bioscience Corp's market cap, and Sanofi SA pays a 5.5% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| SNY | TWST | |
|---|---|---|
Market Cap | $104.83B | $5.45B |
Sector | Health | Health |
52-Week High | $52.34 | $102.88 |
52-Week Low | $41.33 | $24.16 |
Enterprise Value | $121.32B | $5.37B |
Dividend Yield | 5.5% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
